Profit on $475,000 Novartis cancer drug could be a while coming
August 31, 2017 at 12:25 PM EDT
ZURICH, Aug 31 (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.
